Mallinckrodt's higher-dose PENNSAID OK'd in US for knee osteoarthritis pain
This article was originally published in Scrip
Executive Summary
Shares of Mallinckrodt Pharmaceuticals gained as much as 5.1%, or $2.95, on 17 January on the news the FDA had approved the firm's topical nonsteroidal anti-inflammatory drug Pennsaid (diclofenac sodium topical solution) 2% as a treatment for pain of osteoarthritis of the knee.